Brief: Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)
29/07/2025 22:26
Cardiff Oncology Inc CRDF.O: CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM ONGOING RANDOMIZED PHASE 2 FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL (CRDF-004) CARDIFF ONCOLOGY INC - TRIAL SHOWS 49% ORR IN 30MG ONVANSERTIB DOSE ARM CARDIFF ONCOLOGY INC - EARLY PFS DATA FAVORS 30MG ONVANSERTIB DOSE ARM CARDIFF ONCOLOGY INC - ONVANSERTIB WELL-TOLERATED, SHOWS DOSE-DEPENDENT RESPONSE Source text: ID:nGNXVrthT Further company coverage: CRDF.O
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering